학술논문
VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial
Document Type
Abstract
Author
Source
In Annals of Oncology July 2021 32(7):942-944
Subject
Language
ISSN
0923-7534